Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and chimeric adaptors to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance...
Publishing this on the Daily scale as well.
Price needs to find support at the .50 and then the .618 fib levels to move up to the target at 1.618 extension .
Appears to be currently in a falling wedge with a $12.50 bottom which is also the .618 level of the recent price action.
Will be a challenge with the current market conditions but technical indicators show promise.
Price needs to find support at the .50 and then the .618 fib levels to move up to the target at 1.618 extension.
Appears to be currently in a falling wedge with a $12.50 bottom which is also the .618 level of the recent price action.
Will be a challenge with the current market conditions but technical indicators show promise.
First biopharma that is about to flip in our most recent experience. Just look, this baby can't climb forever.
We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in purple with invalidation in red. Fibonacci goals, it is prudent to suggest, are nothing more than...
Hello, it has been a while since I write. With this stock, I wrote Leg B twice. If you read my previous article, you know that there is a Leg B and Leg C, but in this article, I wrote Leg B twice why because Leg C becomes another Leg B unless there is a change in trend.
Thank you for reading! Again, my writing is just an opinion, an idea, and not a...
Guggenheim Maintains Buy on Adicet Bio, Raises Price Target to $32
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting,...
On Friday June 18, ACET was once again traded down to the support at $10. It came back strong, however, and closed near the high of the day. There was heavy volume as buyers obviously saw value at this level.
If it continues up this week, preferably under volume, I would be long with targets at the $12 and $15 levels (previous resistance). A good stop level would...
NASDAQ: ACET price target $27.50 (very bullish/strong buy), it has been coming down from July 20USD touched 10USD and consolidating. Will it reach pre-covid level (48-64USD) ...it has long way to go. But if it reaches avoce 21USD it may get there. I will buy when it touches 12USD again. Or goes above 16USD.
